Related references
Note: Only part of the references are listed.Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
Niels W. C. J. van de Donk et al.
BLOOD (2016)
Syndecan-1 (CD138) Suppresses Apoptosis in Multiple Myeloma by Activating IGF1 Receptor: Prevention by SynstatinIGF1R Inhibits Tumor Growth
DeannaLee M. Beauvais et al.
CANCER RESEARCH (2016)
Treatment of relapsed and refractory multiple myeloma (vol 101, pg 396, 2016)
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD
Saad Usmani et al.
ONCOLOGIST (2016)
Treatment of relapsed and refractory multiple myeloma (vol 101, pg 396, 2016)
Pieter Sonneveld et al.
HAEMATOLOGICA (2016)
BCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic Leukemia
Lorenzo Falchi et al.
MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES (2016)
Ibrutinib in Waldenstrom macroglobulinemia: latest evidence and clinical experience
Jorge J. Castillo et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2016)
Treatment options for relapsed and refractory multiple myeloma
Ajay K. Nooka et al.
BLOOD (2015)
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results
Michael L. Wang et al.
BLOOD (2015)
Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma
Ye Yang et al.
CANCER RESEARCH (2015)
CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Jacob P. Laubach et al.
CLINICAL CANCER RESEARCH (2015)
The Bruton's tyrosine kinase inhibitor ibrutinib in combination with carfilzomib in patients with relapsed or relapsed and refractory multiple myeloma: initial results from a multicenter phase 1/2b study
A. Chari A et al.
Clinical Lymphoma Myeloma & Leukemia (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone
Meletios A. Dimopoulos et al.
HAEMATOLOGICA (2015)
Current treatment landscape for relapsed and/or refractory multiple myeloma
Meletios A. Dimopoulos et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2015)
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2014)
Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease
Rakesh Bam et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappa B
Stuart A. Rushworth et al.
CELLULAR SIGNALLING (2013)
Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy
Joseph J. Buggy et al.
INTERNATIONAL REVIEWS OF IMMUNOLOGY (2012)
Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications
Jana Jakubikova et al.
BLOOD (2011)
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1
S. Vincent Rajkumar et al.
BLOOD (2011)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
S. Vincent Rajkumar et al.
LANCET ONCOLOGY (2010)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Clinically relevant end points and new drug approvals for myeloma
K. C. Anderson et al.
LEUKEMIA (2008)
Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase
Zhengying Pan et al.
CHEMMEDCHEM (2007)
International uniform response criteria for multiple myeloma
B. G. M. Durie et al.
LEUKEMIA (2006)
Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma
ZZ Yang et al.
BLOOD (2006)
Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays
D Chauhan et al.
ONCOGENE (2002)
Phospholipase C-γ2 couples Bruton's tyrosine kinase to the NF-κB signaling pathway in B lymphocytes
JB Petro et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Bruton's tyrosine kinase is required for activation of IκB kinase and nuclear factor κB in response to B cell receptor engagement
JB Petro et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
